TAmiRNA presenting microRNA cardiovascular applications at Eurothrombosis 2018


TAmiRNA presenting microRNA cardiovascular applications at Eurothrombosis 2018


tamirna_logo

Press Release | TAmiRNA GmbH

OCTOBER 02, 2018

Vienna, Austria: – Innovative biotech company TAmiRNA will present latest applications of its microRNA technologies for predicting cardiovascular risk at the upcoming Eurothrombosis Conference, 4. – 6. October, in Barcelona.

TAmiRNA will also contribute two poster presentations prepared in collaboration with clinical researchers. The first will outline ‘Platelet micro-RNAs as a predictor of cardiovascular risk – results from the EXCELSIOR-thrombomiR pilot study”. Followed by insights into how “Circulating MicroRNA Levels Indicate Platelet Activation in Endotoxaemia Despite Platelet P2Y12 Inhibition”. There will be 5 poster sessions during coffee breaks for interaction and discussion with the attendees.

thrombomiR™ microRNA qPCR testing

The presentations will summarize results from the EXCELSIOR-thrombomiR pilot study by Dr. Thomas Nührenberg of the University Heart Center Freiburg at Bad Krozingen. Moreover, results from a study investigating the effects of ticagrelor and clopidogrel on circulating miRNA levels during experimental human endotoxaemia will be presented by Prof. Dr. Manuel Mayr and Dr. Temo Barwari from King´s College London.

The research made use of TAmiRNA’s recently developed thrombomiR™ microRNA qPCR test kit to enable standardized analysis of platelet-derived microRNA to determine platelet function in vivo.

Personalized monitoring

Dr Dellago comments: “The Eurothrombosis Conference represents a valuable opportunity to come into contact with academic and clinical research groups as well as representatives of biotech and pharma companies participating in clinical studies in cardiovascular diseases, who might benefit from our technology.”

“The Eurothrombosis conference is an excellent opportunity to inform the audience on how our technology enables personalized monitoring of anti-platelet therapy efficacy and assessment of bleeding risk due to impaired platelet activation. This opens the way to better risk assessment of adverse cardiovascular events and optimal disease management,” she adds.

About TAmiRNA

Privately owned and headquartered in Vienna, TAmiRNA GmbH is a biotech company specialized in the identification and validation of non-coding RNAs as biomarkers for age-related diseases. The mission of TAmiRNA is to provide clinically useful biomarkers to improve and prolong patient stability, health and quality of life with increasing age.

TAmiRNA specializes in technologies for profiling levels of blood-circulating microRNAs and developing multi-parametric classification algorithms (“signatures”). TAmiRNA uses these technologies to develop minimal-invasive diagnostic tests for early diagnosis and prognosis of disease, or as companion diagnostic tests to support treatment decisions.

TAmiRNA’s pipeline includes developments in osteoporosis, cardiovascular disease, type-2 diabetes, and cancer, which aim to provide ‘microRNA kit’ solutions that enable users to quantify the levels of specific microRNA combinations and platelet function in serum, plasma, urine or other biofluids. The company initially developed kits for bone disease (osteomiR™) and cardiovascular and metabolic diseases (thrombomiRs™).

TAmiRNA also offers contract research services for companies in need of targeted biomarker development. Customers include biopharma companies with drug development programs in human and veterinary medicine, medtech companies and clinical research groups.

More information available at: www.tamirna.com.

About Eurothombosis 2018

The Eurothrombosis Conference was instituted to enhance knowledge of thrombosis in clinical cardiology in Europe and stimulate postgraduate education in thrombosis both at the European Congress of Cardiology and beyond.

It also aims to stimulate clinical research in thrombosis in clinical cardiology in Europe, to be performed preferably by young investigators, bridge basic science in these areas with the clinical practice of Cardiology, and promote knowledge sharing in the thrombosis sector.

The 2018 Eurothrombosis Conference is a three day event opening October 4 at the Barceló Sants Hotel in Barcelona.

The conference is organized by the Thrombosis Working Group of the French-based European Society of Cardiology (ESC) with further information at: http://eurothrombosis2018.com.

Media Contact

Dr. Elisabeth Schraml, Scientific Communications, TAmiRNA GmbH
Tel: +43 (0)660 420 58 56
Email: office@tamirna.com

Resources

Click on TAmiRNA at Eurothrombosis Conference 2018 for other information.
Click on TAmiRNA to contact the company directly.

T1


Supplier Information
Supplier: TAmiRNA GmbH
Address: Muthgasse 18, 1190 Vienna, Austria
Tel: +43 (0)660 420 58 56
Website: www.tamirna.com


Comments are closed.